Inhibitory RNAs to RNA binding proteins hnRNPA1, hnRNPA2 and PTB and uses thereof

US9206426B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9206426-B2
Application numberUS-201113582921-A
CountryUS
Kind codeB2
Filing dateMar 7, 2011
Priority dateMar 5, 2010
Publication dateDec 8, 2015
Grant dateDec 8, 2015

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are methods to reduce or slow down cell growth, for example in a cancer cell comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB. Provided are methods to identify agents which reduce the levels of hnRNPA1, hnRNPA2 or PTB. Provided are methods to identify agents which increase ratio of PKM1/PKM2 proteins, or reduce PKM2 levels, or increase PKM1 levels.

First claim

Opening claim text (preview).

What is claimed is: 1. A method to reduce cell growth of a cancer cell comprising contacting a cancer cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63. 2. A method to treat cancer comprising administering to a subject in need thereof an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB mRNAs, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63. 3. A method to treat cancer comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63. 4. A method to reduce the levels of RNA binding proteins hnRNPA1, hnRNPA2 and PTB in a cell comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63. 5. A method to reduce the amount of hnRNPA1, hnRNPA2 and PTB protein bound to pyruvate kinase pre-mRNA in a cell, comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63. 6. A method to reduce levels of PKM2 RNA or protein in a cell, comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63. 7. A method to increase levels of PKM1 RNA or protein in a cell, comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63. 8. A method to reduce the ratio of PKM2/PKM1 RNA or protein in a cell, comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63. 9. The method of any of claims 1 - 8 , wherein the inhibitory RNA molecule, which targets hnRNPA1, hnRNPA2 or PTB mRNAs is a siRNA. 10. The method of any of claims 1 - 8 , wherein the inhibitory RNA molecule, which targets hnRNPA1, hnRNPA2 or PTB mRNAs is a shRNA. 11. The method of claim 10 , wherein the shRNA is comprised in an RNAi expression vector. 12. The method of any of claims 4 - 8 , wherein the cell is a cancer cell. 13. The method of claim 12 , wherein the cancer cell is brain tumor cell, a glioma tumor cell, or a breast cancer cell. 14. The method of any of claims 4 - 8 wherein the cell expresses PKM2. 15. The method of any of claims 1 - 8 , wherein SEQ ID NOs: 9, 10 and 11 are the sense strand sequence of the inhibitory RNA molecule.

Assignees

Inventors

Classifications

  • C12N15/113Primary

    Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

  • Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

  • interfering nucleic acids [NA] · CPC title

  • Combination therapy · CPC title

  • against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9206426B2 cover?
Provided herein are methods to reduce or slow down cell growth, for example in a cancer cell comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB. Provided are methods to identify agents which reduce the levels of hnRNPA1, hnRNPA2 or PTB. Provided are methods to identify agents which increase ratio of PKM1/PKM2 pro…
Who is the assignee on this patent?
Manley James L, Chen Mo, David Charles, and 2 more
What technology area does this patent fall under?
Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).